Radnor biotech company gets FDA nod to study

iwibacibem.wordpress.com
The approval is the second such studg authorization for the Radnor biotechnologgy company within the pastthree months. In May, PolyMedicx received regulatory approval in Canads to begin human testing of itsantibiotic compound, The company started enrolling patients in a phase-I safety trial for the antibiotix at the end of last PolyMedix, which is focused on developing new therapeutif drug products to treat infectiouzs diseases and acute cardiovascular disorders based on is attempting to commercialize technology licensedx from the . Biomimetic s are small molecule drugs which mimic the activity of but are inexpensive to make and formulatreinto drugs.
Nicholas Landekic , PolyMedixc CEO, said PMX-60056 is in an entirely new class of drug the companuycalls heptagonists. PMX-60056 is designed to reversr the effects of which are used after surgery and duringcardiothoraciv procedures, such as cardiac to prevent blood clots from forming. Existing drugs used to turn off heparinh activity have limitations that include difficulty in adjusting unpredictable efficacy, post-operative bleeding complications and allergic reactions. “Wde are proud to be the first and only companh to be developing this completely new type of Landekic said.
Exton-based signed a license agreement with the Nationapl Cancer Institute for the rights to a monoclonal antibody for a novel antigen identified byNCI researchers. The compan y plans to develop the antibody as a potential treatmenf forprostate cancer. Terms of the deal were not